

	Autoren	Titel	Journal	Jahr	Monat	Ausgabe	Seite	Bemerkung	Print Format A=Abstract V = Volltext	e- For mat
1.	Akilov, O., Khachemoune, A., Hasan, T.	Clinical manifestations and classification of OWCL	IntJDerm	2007		46	132-142	Übersicht	V	X
1a.	Albanese, G., Giorgetti, P., Santagostino, L., Crippa, D., Sala, G.	Cutaneous leishmaniasis. Treatment with itraconazole	Arch Dermatol	1989	Nov	125(11)	1540-2	Azole Itraconazol	A	
2.	Aleixo, J., Nascimento, E., Monteiro, G., Fernandes, M., Ramos, A., Wilson, M., Pearson, R., Jeronimo, S.	Atypical American VL caused by disseminated Leishmania amazonensis infection presenting with hepatitis and adenopathy	Trans R Soc Trop Med Hyg.	2006		100	79-82	VL	V	X
3.	Al-Fouzan, A., Al Saleh, Q., Najem, N., Rostom, A.	Cutaneous Leishmaniasis in Kuwait Clinical Experiences with Itraconazole	IntJDerm	1991	July	30 (7)	519-521	Azole	V	X
4.	Alkhawajah A.	Treatment of CL with antimony: intramuscular versus intralesional administration	Ann Trop Med Parasitol	1997	Dec	91(8)	899-905	IL Antimon	V	X
5.	Allen S., Neal, R.	In vitro anti-Leishmanial activity of compounds in current clinical use for unrelated diseases.	Drugs Exp Clin Res.	1988		14(10)	621-8			
6.	Al-Majali, O., Routh, H., Abuloham, O., Bhowmik, K., Muhsen, M., Hebeheba, H.	A 2-year study of liquid nitrogen therapy in CL	IntJDerm	1997		36	460-462	cryotherapy	V	X
7.	Almeida, R.	Randomized, double – blind study of Stibogluconate Plus Human Granulocyte Macrophage Colony-Stimulating Factor versus Stibogluconate Alone in the Treatment of CL	J Infect Dis	1999		180	1735-1737	Antimon plus GMCSF	V	X
8.	Almeida, R., Brito, J., Machado, P., de Jesus, A., Schriefer, A., Guimaraes, L., Carvalho, E.	Successful treatment of refractory CL with GM-CSF and antimonials	Am. J. Trop Med Hyg	2005		73(1)	79-81	experimental	V	X
9.	Alrajhi, A.	Fluconazole for the Treatment of CL caused by <i>Leishmania major</i>	N Engl J Med	2002	Mar	346(12)	891-895	Azole Fluconazol	V	X

10.	Alsaleh, A., Dvorak, R., Nanda, A.	Ketoconazole in the treatment of CL in Kuwait	IntJDerm	1995	July	34 (7)	495-497	Azole	V	X
11.	Alvar, J, Croft, S., Olliaro, P.	Chemotherapy in the Treatment and Control of Leishmaniasis	Adv Parasitol	2006		61	224-274	Übersicht	V	X
12.	Amato V., Tuon, F., Siqueira, A., Nicodemo, A., Neto, V.	Treatment of Mucosal Leishmaniasis in Latin America: Systematic Review	Am J Trop Med Hyg.	2007	Aug	77(2)	266-274	MCL	V	X
13.	Amato, V. et al.	Mucocutaneous leishmaniasis associated with HIV infection treated successfully with liposomal amphotericin B (AmBisome).	J Antimicrob Chemother	2000		46	341-2	Liposomal Ampho	V	X
14.	Amato, V., Rabello, A., Rotondo-Silva, A., Kono, A., Maldonado, T., Alves, I, Floeter-Winter, L., Neto, V.,, Shikanai-Yasuda, M.	Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients	Acta Tropica	2004	Oct	92(2)	127-32.	Liposomal Ampho	V	X
14a	Amato, V. et al.	Treatment of mucosal leishmaniasis with a lipid formulation of Amphotericin B	Clin Infect Dis	2007		44	311-312	Liposomal Ampho	V	X
15.	Amato, V., Tuon, F., Siqueira, ^a et al	Treatment of MCL in Latin America: systematic review	Am J Trop Med Hyg	2007		77(2)	266-274	MCL	V	X
15a	Ameen, M.	CL: therapeutic strategies and future directions	Expert Opin Pharmacother	2007		8(16)	2689-2699	Übersicht	V	X
16.	Andersen, E.	Comparison of Meglumine Antimoniate and Pentamidine for Peruvian CL	Am. J. Trop Med. Hyg.	2005		72(2)	133-137	Antimon vs Pentamidine	V	X
17.	Andrade-Narváez, F.	Clinical picture of CL due to L.(L.) mexicana in the Yucatan Peninsula, Mexico	Mem Isnt Oswaldo Cruz	2001		96 (2)	162-167	Klinik	V	
18.	Andres, C.	Entscheidend in der primären Immunantwort	Der deutsche Dermatologe	2006		2	93-96	Immunologie	V	
19.	Annonymous	Control of Leishmaniasis	WHO Technical Report Series	1990		793	1-159	Übersicht	V	
20.	Antinori, S., Calattini, E., Longhi, E., Gramiccia, M., Corbellino, M.	CL: an increasing threat for travellers	Clin Microbiol Infect	2005		11	343-346	Übersicht	V	X

21.	Antoniou, M.	Short Report: Treatment failure due to mixed Infection by different Strains of the Parasite <i>Leishmania infantum</i>	Am. J. Trop Med Hyg	2004		71(1)	71-72		V	X
22.	Aram, H., Leibovici, V.	Ultrasound-induced Hyperthermia in the treatment of CL	Cutis	1987	Oct	40	350-353	Heat	V	X
23.	Arana, B.	Randomized, controlled, double-blind trial of Topical treatment of CL with Paromomycin plus Methylbenzethonium Chloride ointment in Guatemala	Am J Trop Med Hyg	2001		65(5)	466-470	Paromomycin MBCL	V	X
24.	Arana, B.	Chemotherapy of CL: a review	Med Microbiol Immunol	2001		190	93-95	Übersicht	V	X
25.	Ardehali, S.	The characterization of <i>Leishmania</i> from patients with lymphadenopathy in Shiraz, Iran	Trans R Soc Trop Med Hyg.	1995		89	370-371		V	X
26.	Arevalo, J.	Successful Treatment of Drug-Resistant CL in Humans by Use of Imiquimod, an Immunomodulator	Clin Infect Dis	2001		33	1847-1851	Imiquimod	V	X
27.	Arevalo, J., Ramirez, L., Adai, V., Zimic, M., Tulliano, G. et al	Influence of <i>Leishmania</i> (Viannia) species on the response to antimonial treatment in patients with American tegumentary Leishmaniasis	J Infect Dis	2007	June	195	1846-1851		V	X
28.	Arevalo, J., Tulliano, G., Quispe, A., Spaeth, G., Matlashewski, G., Llanos-Cuentas, A., Pollack, H.	Role of imiquimod and parenteral meglumine antimonite in the initial treatment of CL	Clin Infect Dis	2007		44	1549-1554	Imiquimod	A	
29.	Armijos, R.	Safety, immunogenicity, and efficacy of an autoclaved <i>Leishmania amazonensis</i> vaccine plus BCG adjuvant against New World CL	Vaccine	2003	June		1320-1326		V	
30.	Armijos, R., Weigel, M., Calvopina, M., Mancheno, M., Rodriquez, R.	Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimonite for New World CL	Acta Tropica	2004	July	91(2)	153-60	Paromomycin vs Antimon	V	X

31.	Aronson, N., Wortmann, G., Johnson, S., Jackson, J., Gasser, R., Magill, A., Endy, T., Coyne, P., Grogl, M., Benson, P., Beard, J., Tally, J., Gambel, J., Kreutzer, R., Oster, C.	Safety and Efficacy of Intravenous Sodium Stibogluconate in the Treatment of Leishmaniasis: Recent U.S. Military Experience	Clin Infect Dis	1998		27	1457-64	Antimon	V	
32.	Aseri, S.	The role of rifampicin in the management of CL	Quarterly J of Med	2000		93	733-737	Rifampicin	V	
33.	Asilian, A., Sadeghinia, A., Faghihi, G., Momeni, A., Harandi, A.	The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of CL	Ann Trop Med Parasitol	2003	July	97(5)	493-498	Cryotherapy vs IL Antimon vs Cryotherapy plus IL Antimon	V	
34.	Asilian, A.	Treatment of CL with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran	Bulletin WHO	2003		81(5)	353-359	Paromomycin	V	X
35.	Asilian, A., Davami, M.	Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of OWCL: a placebo-controlled, randomized clinical trial	Clin Exp Dermatol	2006	Sep	31(5)	634-637	PDT vs Paromomycin	V	X
36.	Asilian, A., Jalayer, T., Whitworth, J., Ghasemi, R., Nilforooshzadeh, M., Olliaro, P.	A randomized, placebo – controlled trial of a Two – week regimen of Aminosidine (Paromomycin) Ointment for Treatment of CL in Iran	Am. J. Trop. Med Hyg	1995		53(6)	648-651	Paromomycin	V	X
37.	Asilian, A., Sadeghinia, A., Faghihi, G., Momeni, A.	Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate alone for	IntJDerm	2004	April	43 (4)	281-3	Cryotherapy vs IL Antimon plus cryotherapy	V	X

		the treatment of CL								
38.	Azeredo-Coutinho RB, Mendonça SC, Callahan H, Portal AC, Max G	Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis.	J Parasitol.	2007	Jun	93(3)	688-693	Antimon	V	X
39.	Badaro, R.	The Role of Interferon in the Treatment of VL and DCL	J Infect Dis	1993		167 (Suppl 1)	13-17	Interferon	V	
40.	Bafica, A., Oliveira, F., Freitas, L., Nascimento, E., Barral, A.	ACL unresponsive to antimonial drugs: successful treatment using combination of N-Methylglucantime Antimonate plus Pentoxifylline	IntJDerm	2003		42	203-207	Pentoxifylline	V	X
41.	Bailey, M.	Clinical Guidelines for the Management of CL in British Military Personnel	J R Army Med Corps	2005		151	73-80	Übersicht	V	X
42.	Bailey, M., Lockwood, D.	CL	Clin Dermatol	2007	Mar-Apr	25(2)	203-211	Übersicht	V	X
43.	Ballou, W., McClain, J., Gordon, D., Shanks, G., Andujar, J., Berman, J., Chulay, J.	Safety an efficacy of high-dose sodium stibogluconate therapy of American CL	Lancet	1987	July	2 (8549)	13-6	Antimon	V	
44.	Banzet, S.	Epidemics of CL in military personnel working in French Guiana	Med Trop (Mars)	2000		60(3)	297-302	Übersicht	A	
45.	Barral, A., Barral-Netto M., Almeida, R., Ribeiro de Jesus, A., Grimaldi, G., Netto, E., Santos, I., Bacellar, O., Carvalho, E.	Lymphadenopathy associated with Leishmanis braziliensis cutaneous infection	Am J Trop Med Hyg	1992		47(5)	587-592	Übersicht	V	X
46.	Barral, A., Guerreiro, J., Bohmfim, G., Correia, D., Barral-Netto M., Carvalho, A.	Lymphadenopathy as the first sign of human cutaneous infection by Leishmanis braziliensis	Am J Trop Med Hyg	1995		53(3)	256-259	Übersicht	V	X
47.	Barral, A., Pedral Sampaio, D., Grimaldi, G., Momen,	Leishmaniasis in Bahia, Brazil: evidence that Leishmania	Am. J. Trop. Med Hyg	1991	May	44 (5)	536-46	Übersicht	V	X

	H., McMahonPratt,D., Ribeiro, A.,Almeida, R.,Badardo, R.,Barral Netto, M., Carvalho, E.	amazonensis produces a wide spectrum of clinical disease								
48.	Baumm, K., Berens, R.	Successful treatment of CL with Allopurinol after failure of treatment with ketoconazole	Clin Infect Dis		1994	18	813-815	Allopurinol	V	X
49.	Belkaid, Y	The role of interleukin (IL) – 10 in the persistence of <i>Leishmania major</i> in the Skin after Healing and the Therapeutic Potential of Anti – IL – 10 Receptor Antibody for Sterile Cure	J Exp Med	2001	Nov	194(10)	1497-1506	Immunologie	V	
50.	Belli, A.	Simplified Polymerase Chain Reaction Detection of New World Leishmania in Clinical Specimens of CL	Am. J. Trop. Med Hyg	1998		58(1)	102-109	Diagnostik	V	X
51.	Ben Salah, A., Zakraoui, H., Zaatour, A., Ftaiti, A., Zaafouri, B., Garraoui, A., Olliaro, P., Dellagi, K., Ben, I.	A randomized, placebo – controlled trial in Tunisia treating CL with paromomycin ointment	Am J. Trop. Med Hyg	1995	Aug	53 (2)	162-6	Paromomycin	A	X
52.	Berman, J.	Human Leishmaniasis: Clinical, Diagnostic, and Chemotherapeutic Developments in the last 10 Years	Clin Infect Dis	1997		24	684-703	Übersicht	V	
53.	Berman, J.	Recent Developments in Leishmaniasis: Epidemiology, Diagnosis, and Treatment	Current Infectious Dis Rep	2005		7	33-38	Übersicht	V	
54.	Berman, J.	Current treatment approaches to Leishmaniasis	Current Opinion in Infect Dis	2003		16	397-401	Übersicht	V	
55.	Berman, J., Chulay, J., Hendricks, L., Oster, C.	Susceptibility of clinically sensitive and resistant leishmania to pentavalent antimony in vitro	Am J. Trop. Med Hyg	1982		31 (3)	459-465	Antimon	V	X
56.	Berman, J., Neva, F.	Effect of temperature on multiplication of <i>Leishmania amastigotes</i> within human monocyte-derived macrophages in	Am J. Trop. Med Hyg	1981		30 (2)	318-321	Heat	V	X

		vitro								
57.	Berman. J., Bryceson, A., Croft, S., Engel, J., Gutteridge, W., Karbwang, J., Sindermann, H., Soto, J., Sundar, S., Urbina, J.	Miltefosine: issues to be addressed in the future	Trans R Soc Trop Med Hyg.	2006		100S	S41-44	Miltefosine	V	X
58.	Bhattacharya,S.,Jha,T.,Sund ar,S.,Thakur,C.,Engel,J.,Sin dermann,H.,Junge,K.,Karbw ang,J.,Bryceson,A.,Bermann ,J.	Efficacy and Tolerability of Miltefosine for Childhood Visceral Leishmaniasis in India	Clin Infect Dis	2004		38	217-21	Miltefosine VL	V	X
59.	Blum, J.	Therapie kutaner und mukokutaner Leishmaniosen	Dtsch. Med. Wschr.	1994		119	1169-1172	Übersicht	V	X
60.	Blum, J.	Treatment of CL among travellers	J Antimicrob Chem	2004		53	158-166	Übersicht	V	X
61.	Boakye D, Wilson M, Kweku M.	A Review of Leishmaniasis in West Africa	Ghana Med J.	2005	Sep	39(3)	94-97	Epidemiologie		
62.	Bormann, G.	Kutane amerikanische Leishmaniose - Besonderheiten der Diagnostik und Therapie	Dtsch. Med. Wschr.	2003		128	2065-2068	Übersicht	V	X
63.	Brito, M.	Dynamics of the antibody response in patients with therapeutic or spontaneous cure of American CL	Trans R Soc Trop Med Hyg.	2001		95	203-206	Immunologie	V	X
64.	Brown, M., Noursadeghi, M., Boyle, J., Davidson, R.	Sucessful liposomal amphotericin B treatment of Leishmania braziliensis CL	Br J Derm	2005		153	203-205	Liposomal Ampho B	V	X
65.	Bryceson, A., Murphy, A., Moody, A.	Treatment of Old World CL with aminosidine ointment: results of an open study in London	Trans R Soc Trop Med Hyg.	1994		88	226-228	Paromomycin	V	X
66.	Burbach, G.	Leishmaniosen – Grundlagen, Klinik, Diagnostik und Therapie	Dtsch. Med. Wschr.	1999		124	88-93	Übersicht	V	X
67.	Calvopina, M., Gomez, E., Sindermann, H., Cooper, P., Hashiguchi, Y.	Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment	Am J Trop Med Hyg	2006	Dec	75(6)	1074-1077	Miltefosine	V	X

68.	Calvopina,M., Guevara,A., Armijos,R., Hashiguchi,Y.,Davidson,R., Cooper,P.	Itraconazole in the treatment of New World mucocutaneous leishmaniasis	IntJDerm	2004	Sep	43(9)	659-63	Azole Itraconazol	V	X
69.	Calvopina,M., Uezato, H., Gomez, E., Korenaga, M., Nonaka, S., Hashiguchi, Y.	Leishmania recidiva cutis due to Leishmania (V) panamensis in subtropical Ecuador: isoenzymatic characterization	IntJDerm	2006		45	116-120	Diagnostik	V	X
69a	Calza, L., D'Antuono, A., Marinacci, G. et al	Disseminated cutaneous leishmaniasis after visceral disease in a patient with AIDS	J Am Acad Dermatol	2004	Mar	50(3)	461-5.		A	
69b	Campos-Muñoz L. et al.	Leishmania braziliensis: report of a pediatric imported case with response to liposomal amphotericin B	Acta Dermo-sifiliogr	2007		98 (1)	42-4	Ampho B	A	
70.	Canaan, T.	Die Jerichobeule	Zentralblatt f. Bakteriologie	1914		73	110-119		V	
71.	Cardo, L.	Leishmania: risk for the blood supply	Transfusion	2006		46	1641-1645	Übersicht	V	X
72.	Carvalho EM, Barral A, Costa JM, Bittencourt A, Marsden P.	Clinical and immunopathological aspects of disseminated cutaneous leishmaniasis	Acta Trop	1994	Apr	56(4)	315-25			
73.	Catorze,G.,Alberto,J.,Afonso,A.,Vieira,R.,Cortes,S.,Campino,L.	Cutaneous lesions following treatment of VL	Ann Dermatol Venerol	2006	Jan	133(1)	39-42	VL	A	
74.	Chulay,J.,Spencer,H.,Mugambi,M.	Electrocardiographic changes during treatment of leishmaniasis with Pentavalent antimony	Am. J. Trop. Med Hyg	1985		34(4)	702-9	Antimon	V	X
75.	Clos, J.	Proceedings of an International Workshop held at the Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany, 10 – 11 Nov 2000	Med Microbiol Immunol	2001		190	1-2		V	
76.	Colmenares, M., Kar, S., Goldsmith-Pestana, K., McMahon-Pratt, D.	Mechanisms of pathogenesis: differences among Leishmania species	Trans R Soc Trop Med Hyg.	2002		96	S1/3-S1/7	Pathogenese	V	X

77.	Consigli, J., Daniello, C., Gallerano, V., Papa, M., Guidi, A.	CL: Successful treatment with itraconazole	IntJDerm	2006		45	46-49	Azole	V	X
78.	Convit, J.	Leishmaniasis: Immunological and clinical aspects and vaccines in Venezuela	Clinics in Dermatology	1996	Sep-Oct	14(5)	479-87.			
79.	Costa, J.	O Uso Clinico das pentamidinas Com especial referencia nas Leishmanioses	Acta Amazonica	1993		23(2-3)	163-172	Pentamidine	V	
80.	Costa J., Marsden PD, Llanos-Cuentas EA, Netto EM, Carvalho EM, Barral A, Rosa AC, Cuba CC, Magalhaes AV, Barreto AC.	Disseminated cutaneous leishmaniasis in a field clinic in Bahia, Brazil: a report of eight cases	J Trop Med Hyg	1986	Dec	89(6)	319-23			
81.	Croft, S.	Chemotherapy of Leishmaniasis	Curr Pharm Des	2002		8(4)	319-342	Übersicht	V	X
82.	Croft, S.	Drug sensitivity of CL species: some unresolved problems	Trans R Soc Trop Med Hyg.	2002		Suppl 1	127-129	Übersicht	V	X
83.	Croft, S.	Chemotherapy of Trypanosomiasis and CL	TRENDS in Parasitology	2005		20(20)	1-6	Übersicht	V	X
84.	Croft, S.	CL- current chemotherapy and recent advances in the search for novel drugs	TRENDS in Parasitology	2003	Nov	19(11)	502-508	Übersicht	V	X
85.	Croft, S., Davidson,R., Thornton,E.	Liposomal amphotericin B in the treatment of visceral leishmaniasis	J Antimicrob Chemoth	1991		28	111-18	Liposomal Ampho	V	
86.	Croft, S., Sundar, S., Fairlamb, A.	Drug resistance in leishmaniasis	Clin Microbiol Rev	2006	Jan	19(1)	111-26	Übersicht	V	X
87.	Cruz, A., Rainey, P., Herwaldt, B., Stagni, G., Palacios, R., Trujillo, R., Saravia, N.	Pharmacokinetics of Antimony in children treated for Leishmaniasis with meglumine antimoniate	J Infect Dis	2007	Feb	195	602-608	Antimone	V	X
88.	Davidson, R.	A topical nitric oxide – generating therapy for CL	Trans R Soc Trop Med Hyg.	2000		94	319-322	Nitric oxide	V	X
89.	Davidson, R.	Leishmaniasis	Infect Dis	1999		2	32.1-32.6	Übersicht	V	
90.	Davidson, R., Martino, L., Gradoni, L., Giacchino,	Liposomal amphotericin B (AmBisome) in Mediterranean	Quarterly J of Med	1994		87	75-81	Liposomal Ampho	V	

	R., et al	VL: a multi – centre trial								
91.	Davidson,R.,Croft,S.,	Recent advances in the treatment of visceral leishmaniasis	Trans R Soc Trop Med Hyg.	1993		87	130 f und 140	Übersicht	V	X
92.	Davidson,R.,Croft,S.,Scott, A. et al	Liposomal amphotericin B in drug – resistant visceral leishmaniasis	Lancet	1991	May	337	1061-1062	Liposomal Ampho	A	
93.	De Oliveira Camera, P., Junger, J., do Espirito Santo Silva Pires, F., Mattos, M., Oliveria-Neto, M., Fernandes, O., Pirmez, C.	Haematogenous dissemination of Leishmania (Viannia) braziliensis in human American tegumentary leishmaniasis	Trans R Soc Trop Med Hyg.	2006		100	1112-1117		V	X
94.	De Oliveira Schubach, A..	Retrospective study of 151 patients with CL treated with meglumine antimoniate	Rev Soc Bras Med Trop	2005	Mai- Jun	38(3)	213-217	Antimon	V	X
95.	De Vries, P., van der Meide, W., Godfried, M., Schallig, H., Dinant, H., Faber, W.	Quantification of the response to miltefosine for VL by QT-NASBA	Trans R Soc Trop Med Hyg.	2006		100	1183-1186	Miltefosine VL	V	X
96.	Dedet, J., Pratlon, F.	Leishmaniasis	Manson´s Tropical Diseases 21 st edition	2004		Chapter 75	s.1339 ff	Übersicht	V	
97.	Dedet, J-P.	CL in French Guiana; a Review	Am J Trop Med Hyg	1990		25-28	89-147	Epidemiologie	V	X
98.	Delobel, P.	Rhabdomyolysis associated with pentamidine isethionate therapy for ACL	J Antimicrob Chem	2003		51	1319-1320	Pentamidine	V	X
99.	Desjeux, P.	Worldwide increasing risk factors for Leishmaniasis	Med Microbiol Immunol	2001		190	77-79	Übersicht	V	
100.	Desjeux, P.	The increase in risk factors for leishmaniasis worldwide	Trans R Soc Trop Med Hyg.	2001		95	239-243	Übersicht	V	X
101.	Dogra, J., Aneja, N., Behari, B., Nath Mishra, S.	CL in India Clinical Experience with Itraconazole	IntJDerm	1990	Nov	29(9)	661-662	Azole Itraconazole	V	X
102.	Dogra,J.,Saxena,V.,	Itraconazole and leishmaniasis: a randomised double-blind trial in cutaneous disease	IntJPara	1996	Dec	26(12)	1413-5	Azole Itraconazol	V	

103.	Dowlati, Y.	CL: clinical aspects	Clinics in Derm	1996		14	425-431	Klinik	V	
104.	Elamin, E.	Uncommon clinical presentations of CL in Sudan	Trans R Soc Trop Med Hyg.	2005		99	803-808	Klinik	V	X
105.	El-Darouti, M.	CL. Treatment with combined cryotherapy and intralesional stibogluconate injection	IntJDerm	1990	Jan-Feb	29(1)	56-59	Cryotherapy plus IL Antimon	V	X
106.	El-Hajj, L., Thellier, M., Carriere, J., Bricaire, F., Danis, M., Caumes, E.	Localized CL imported into Paris : a review of 39 cases	IntJDerm	2004		43	120-125	Übersicht	V	X
107.	El-Hassan, A.	Leishmaniasis in Sudan: 1. CL	Trans R Soc Trop Med Hyg.	2001		Supplement 1	1-17		V	X
108.	El-Hassan, A.	Sudanese mucosal leishmaniasis:epidemiology, clinical features, diagnosis, immune responses and treatment	Trans R Soc Trop Med Hyg.	1995		89	647-652	MCL	V	X
109.	El-On J, Bazarsky E, Sneir R.	Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator Imiquimod	Exp Parasitol	2007	Jun	116(2)	156-62	Imiquimod plus Paromomycin	V	X
110.	El-On, J.	Topical Chemotherapy of CL	Parasitology Today	1988		4(3)	76-81	Paromomycin	V	
111.	El-On, J. Cawich, F., Evans, D., Weinrauch, L.	Topical treatment of CL in Belize:in vitro and in vivo studies with Leishmanias mexicana	IntJPara	1993		23 (1)	121-127	Paromomycin	V	
112.	El-On, J. Jacobs, G., Witztum, E., Greenblatt, C.	Development of topical treatment for CL caused by Leishmania major in experimental animals	Antimicrob Agents Chemother	1984		26 (5)	745-751	Paromomycin	V	
113.	El-On, J., Halevy, S., Grunwald, M., Weinrauch, L.	Topical treatment of OWCL caused by Leishmania major: A double-blind control study	J Am Acad Dermatol	1992		27	227-31	Paromomycin	V	
114.	El-On, J., Livshin, R., Even-Paz, Z., Hamburger, D., Weinrauch, L.	Topical Treatment of CL	J Invest Dermatol	1986		87	284-88	Paromomycin	V	
115.	El-On, J., Livshin, R., Even-	Topical Treatment of CL	BMJ	1985	Nov	291	1280-1281	Paromomycin	V	X

	Paz, Z., Weinrauch, L.									
116.	El-On, J., Messer, G.	Leishmania major: Antileishmanial activity of Methylbenzethonium chloride	Am. J. Trop. Med Hyg	1986			1110-1116	Paromomycin	V	X
117.	El-On, J., Sulitzeanu, A., Schnur, L.	Leishmania major: resistance of promastigotes to paromomycin, and susceptibility of amastigotes to paromomycin-methylbenzethonium chlorid ointment	Ann Trop Med Parasitol	1991		85 (3)	323-328	Paromomycin	V	
118.	El-Safi, S., Murphy, A., Bryceson, A., Neal, R.	A double-blind clinical trial of the treatment of CL with paromomycinointment	Trans R Soc Trop Med Hyg.	1990		84	690-691	Paromomycin	V	X
119.	Enk, C., Fritsch, C., Jonas, F., Nasereddin, A., Ingber, A., Jaffe, C., Ruzicka, T.	Treatment of cutaneous leishmaniasis with photodynamic therapy	Arch Dermatol	2003.		139	432-434.	PDT		
120.	Escobar, P.	Sensitivities of CL species to hexadecylphosphocholine (miltefosine), ET – 18 – OCH (edelfosine) and amphotericin B	Acta Tropica	2002		81	151-157	Miltefosine	V	X
121.	Escobar, P.	Activities of Hexadecylphosphocoline (Miltefosine), AmBisome, and Sodium Stibogluconate (Pentostam) against <i>Leishmania donovani</i> in Immunodeficient scid Mice	Antimicrob Agents Chemother.	2001	June	45(6)	1872-1875	Miltefosine VL Liposomal Ampho Antimon	V	
122.	Esfandiarpour, I., Alavi, A.	Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of CL	IntJDerm	2002	Aug	41(8)	521-4	Allopurinol Antimon	V	X
123.	Evans, D.	Handbook on Isolation, Characterization and Cryopreservation of Leishmania	TDR, UNDP/World bank/WHO	1989			1-45	Übersicht	V	X
124.	Faghihi, G.	Treatment of CL with either topical paromomycin or intralesional meglumine antimoniate	Clin Exp Dermatol	2003	Jan	28(1)	13-16	Paromomycin vs IL Antimon	V	X

125.	Faris, R., Jarallah, J., Khoja, T., al-Yamani, M.	Intralesional treatment of CL with sodium stibogluconate antimony	IntJDerm	1993	Aug	32(8)	610-2	IL Antimon	V	X
126.	Firooz, A.	Intralesional injection of 2% zinc sulfate solution in the treatment of acute OWCL: a randomised, double-blind, controlled clinical trial	J Drugs Dermatol	2005	Jan-Feb	4 (1)	73-9	IL Zinc	A	
127.	Firooz, A., Khamesipour, A., Ghoorchi, M., Nassiri-Kashani, M., Eskandari, S., Khatami, A., Hooshmand, B., Gorouhi, F., Rashighi-Firoozabadi, M., Dowlati, Y.	Imiquimod in combination with meglumine antimoniate for CL: a randomized assessor-blind controlled trial.	Arch Dermatol	2006	Dec	142(12)	1575-1579	Imiquimod	V	X
128.	Firooz, A., Khatami, A., Dowlati, Y.	Itraconazole in the treatment of CL	IntJDerm	2006		45	1446-1447	Azole	V	X
129.	Fischer, C.	Development status of miltefosine as first oral drug in visceral an CL	Med Microbiol Immunol	2001		190	85-87	Miltefosine VL	V	
130.	Franke, E.	Efficacy and Toxicity of Sodium Stibogluconate for MCL	Ann Int Med	1990	Dec	113(12)	934-940	Antimon	V	
131.	Frankel, D.	Study puts a number on poor compliance in the elderly	Lancet	1998	May	351	1495		V	X
132.	Gadelha,A.,Oliveira,W.,Assuncao,I.,Dourado,H.	Tratamento da leishmaniose tegumentar americana com injecoes intralesionais de n-metil-glucamina	Ann Bras Dermatol	1990		65(4)	201-203	IL Antimon	V	
133.	Garcia, A., Parrado, R., de Doncker, S., Bermudez, H., Dujardin, H.	American tegumentary Leishmaniasis: direct species identification of Leishmania in non-invasive clinical samples	Trans R Soc Trop Med Hyg.	2006				Diagnostik	V	X
134.	Gardlo, K., Hanneken, S., Ruzicka, T., Neumann, N.	Photodynamic therapy of cutaneous leishmaniasis. A promising new therapeutic modality	Hautarzt	2004		55	381-383	PDT		
135.	Gardlo, K., Horska, Z., Enk, C., Rauch, L., Megahed, M., Rudzicka, T., Fritsch, C.	Treatment of CL by photodynamic therapy	J Am Acad Dermatol	2003	June	48	893-896	PDT	V	X

136.	Garnier, T., Croft, S.	Topical Treatment for CL	Current Op Invest Drugs	2002		3 (4)	538-544	Paromomycin	V	X
137.	Gasser RA Jr, Magill AJ, Oster CN, Franke ED, Grogl M, Berman JD	Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis	Clin Infect Dis	1994	Jan;	18(1)	83-90	Antimon	V	
138.	Ghosn, S.	Evaluation of sodium stibogluconate in the treatment of CL in Syria	Curr Med Res Opin	1979		6(4)	280-283	Antimon	A	
139.	Gontijo, B.	Leishmaniose tegumentar americana American CL	Rev Soc Bras Med Trop	2003	Jan.-Feb	36(1)	71-80	Übersicht	V	X
140.	Gradoni, L.	Visceral Leishmaniasis Treatment, Italy	Emerging Infect Dis	2003	Dec	9(12)	1617-20	VL	V	
141.	Grevelink, S., Lerner, E.	Leishmaniasis	J Am Acad Dermatol	1996		34	257-272	Übersicht	A	
142.	Grimaldi, G., Schottelius, J.	Leishmaniasis – Their relationships to maonoxenous and dixenous trypanosomatids	Med Microbiol Immunol	2001		190	3-8	Taxonomie	V	
143.	Grimaldi, G., Tesh, R.	Leishmaniasis of the New World: Current Concepts and Implications for Future Research	Clin Microbiol Reviews	1993	Jul		230-250	Übersicht	V	
144.	Grimaldi, G., Tesh, R., McMahon-Pratt, D.	A review of the geographic distribution and epidemiology of Leishmaniasis in the New World	Am J Trop Med Hyg	1989		41(6)	687-725	Epidemiologie	V	X
145.	Groll, A.	Failure of Amphotericin B Lipid Complex in the Treatment of CL	Clin Infect Dis	1998		26	1006 f	Liposomal Ampho	V	
146.	Guderian, R., Chico, M., Rogers, M., Pattishall, K., Grogl, M., Berman, J.	Palcebo controlled Treatment of Ecuadorian CL	Am J Trop Med Hyg	1991		45 (1)	92-97	Allopurinol vs Antimon	V	X
147.	Gunduz, K.	Recidivans CL unresponsive to liposomal amphotericin B (AmBisome)	J Eur Acad Dermatol Venereol	2000	Jan	14(1)	11-13	Liposomal Ampho	A	
148.	Gurei, M., Tatli N., Ozbilge, H., Erel, O., Seyrek, A., Kocyigit, A., Ulukanligil, M.	Efficacy of cryotherapy and intralesional pentostam in treatment of CL	J Egypt Soc Parasitol	2000	Apr	30(1)	169-76	Cryotherapy vs IL Antimon	V	X
149.	Gurel, M., Ulukanligil, M., Ozbilge, H.	Cutaneous leishmaniasis in Sanliurfa: epidemiologic and	IntJDerm	2002		41	32-37	Übersicht	V	X

		clinical features of the last four years (1997-2000)								
150.	Gustavo, A.	Comparison of CL Due to <i>Leishmania (Viannia) braziliensis</i> and <i>L.(V.) guyanensis</i> in Brazil: Clinical Findings and Diagnostic Approach	Current Infect Dis	2001	May	32	1304-1312	Klinik	V	
151.	Hadighi, R., Moheballi, M., Boucher, P., Hajjaran, H., Khamesipour, A., Quellette, M.	Unresponsiveness to Glucantime Treatment in Iranian CL due to Drug – Resistant <i>Leishmania tropica</i> Parasites	Plos Med	2006	May	3 (5)	1-9	Antimon	V	X
152.	Handman, E.	Leishmaniasis: Current Status of Vaccine Development	Clinical Microbiol Reviews	2001		14(2)	229-243	Übersicht	V	
153.	Harms, G.	A randomized trial comparing a pentavalent antimonial drug and recombinant interferon in the local treatment of CL	Trans R Soc Trop Med Hyg.	1991		85	214-216	Interferon plus Antimon	V	X
154.	Harms, G.	Leishmaniosen – Importierte Krankheiten	Deutsches Ärzteblatt	2000	Aug	31-32	1589-1592	Übersicht	V	X
155.	Harms, G., Chehade, A., Racz, P., Douba, M., Naiff, R., Feldmeier, H., Zwingenberger, K., Talhari, S., Mouakeh, A., Näkel, L., Kremsner, P., Bienzle, U.	Effects of intradermal Gamma – Interferon in CL	Lancet	1989	June	10	1287-1292	Interferon	V	
156.	Harris, E.	Single-Step Multiplex PCR Assay for Characterization of New World <i>Leishmania</i> Complexes	J Clinical Microbiology	1998	July	36(7)	1989-1995	Diagnostik	V	
157.	Hartzell, J., Aronson, N., Ngaraja, S., Whitman, T., Hawkes, C., Wortmann, G.	Varicella Zoster Virus Meningitis complicating sodium stibogluconate treatment for CL	Am J. Trop Med Hyg	2006		74(4)	591-592	Antimone	V	X
158.	Heinzl, S.	Amphotericin B	Arzneimitteltherapie	1995		20	1-8	liposomal Amphotericin	V	
159.	Hellier, I.	Treatment of OWCL by Pentamidine Isethionate	Dermatology	2000		200	120-123	Pentamidine	V	
160.	Hepburn, N.	CL: Current and future management	Expert Rev. Anti-infect.	2003		1 (4)	563-570	Übersicht	v	

			Ther.							
161.	Hepburn, N., Tidman, M., Hunter, J.	Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of ACL	Trans R Soc Trop Med Hyg.	1994		88	700-703	Paromomycin vs Antimon	V	X
162.	Hepburn, N..	CL	Clin Exp Dermatol	2000		25	363-370	Übersicht	V	X
163.	Herwaldt, B.	Recommendations for treating Leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies	Am J Trop Med Hyg	1992		46(3)	296-306	Antimon	V	X
164.	Herwaldt, B.	Miltefosine – The Long – Awaited Therapy for visceral leishmaniasis?	N Engl J Med	1999	Dec	9	1840-1842	Miltefosine VL	V	
165.	Herwaldt, B.	ACL in U. S. Travelers	Ann Int Med	1993	May	118 (10)	779-784	Übersicht	V	
166.	Herwaldt, B.	Leishmaniasis	Lancet	1999	Oct	354	1191-99	Übersicht	V	X
167.	Ilg, T.	Lipophosphoglycan of the protozoan parasite Leishmania: stage - and species – specific importance for colonization of the sandfly vector, transmission and virulence to mammals	Med Microbiol. Immunol	2001		190	13-17		V	
168.	Iraji, F.,	Comparison of intralesionally injected zinc sulfate with meglumine antimoniate in the treatment of acute CL	Dermatology	2004		209 (1)	46-49	IL Antimon vs IL Zinc	A	
169.	Iraji, F., Sadeghinia, A.	Efficacy of paromomycin ointment in the treatment of CL: results of a double-blind, randomized trial in Isfahan, Iran	Ann Trop Med Parasitol	2005		99 (1)	3-9	Paromomycin	V	X
170.	Jappe, U.	Unusual Skin Infections in Military Personnel	Clinics in Derm	2002		20	425-434		V	
171.	Jauréguiberry S., Graby G., Caumes E.	Efficacy of short Course Intramuscular Pentamidine Isethionate Treatment on Old world Cutaneous Leishmaniasis in 2 Patients	Clin Infect Dis	2006		42	1812-1813	Pentamidine	V	X
172.	Jolliffe, D.	CL from belize – treatment with Ketoconazole	Clin Exp Dermatol	1986		II	62-68	Azole	V	X

173.	Junaid, A.	Treatment of CL with infrared heat	IntJDerm	1986	Sept	25 (7)	470-471	Heat	V	X
174.	Just, S., Schepers, G., Piotrowski, M., Saint, S., Kauffman, C.	Improving the safety of intravenous admixtures: Lessons learned from a pentostam overdose	J Qual Pat Safety	2006	July	32 (7)	366-372	Antimon	V	X
175.	Kafetzis, D., Maltezou, H.	Visceral leishmaniasis in paediatrics	Current Opinion Infect Dis	Jun	2002	15(3)	289-94	VL	A	
176.	Kellum R. et al	Treatment of CL with an intralesional antimonial drug (Pentostam)	J Am Acad Dermatol	1986		15	620-622	Antimon IL	F	
177.	Kharfi, M.	Childhood Leishmaniasis: Report of 106 cases	Derma Online J	2005		10(2)		Klinik	V	
178.	Khatami A, Firooz A, Gorouhi F, Dowlati Y.	Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials.	J Am Acad Dermatol	2007	Aug	57(2)	335-364	Übersicht	V	X
179.	Kochar, D., Saini, G., Kochar, S., Sirohi, P., Bumb, R., Mehta, R., Purohit, S.	A double blind, randomized placebo controlled trial of rifampicin with omeprazole in the treatment of human CL	J Vect Borne Dis	2006		43	161-167	Experimental	V	X
180.	Kochar, D., Aseri, S., Sharma, B., Bumb, R., Mehta, R., Purohit, S.	The Role of rifampicin in the management of CL	Association of Physicians	2000		93	733-737	Rifampicin	V	
180a	Konecny, P., Stark, D.	An Australian case of New World cutaneous leishmaniasis.	Med J Aust	2007	Mar	19;186(6)	315-7	Ampho B	V	X
181.	Krause, G	Topical Paromomycin/Methylbenzethonium Chloride Plus Parenteral Meglumine Antimonate as Treatment of ACL: Controlled Study	Clin Infect Dis	1999		29	466-467	Paromomycin plus Antimon	V	
182.	Krause, G.	Topical treatment of ACL with paramomycin and methylbenzethonium chloride: a clinical study under field conditions in Ecuador	Trans R Soc Trop Med Hyg.	1994		88	92-94	Paromomycin	V	X
183.	Kumaresan, M., Kumar, P.	Localized CL in South India:	Ind J Derm	2007	Sept	73 (5)	361-362	Ketoconazol	V	X

		Sucessful treatment with Ketoconazole								
184.	Lai A Fat, E., Vrede, M., Soetosenojo, R., Lai A Fat, R.	Pentamidine the drug of choice for the treatment of CL in Surinam	IntJDerm	2002		41	796-800	Pentamidine	V	X
185.	Lainson, R.	Leishmania mexicana: the epidemiology of dermal leishmaniasis in British Honduras	Trans R Soc Trop Med Hyg.	1965		57	242-265		V	X
186.	Lambertucci, J., Franca, B., Queiroz, E.	Acute pancreatitis caused by meglumine antimoniate given for the treatment of visceral leishmaniasis	Rev Soc Bras Med Trop	2004	Jan - Feb	37	74 - 75	Antimon	V	X
187.	Larabi, M., Yardley, V., Loiseau, P., Appel, M., Legrand, P., Gulik, A., Borjes, C., Croft, S., Barratt, G.	Toxicity and Antileishmanial Activity of a New Stable Lipid Suspension of Amphotericin B	Antimicrob Agents Chemother	2003	Dec	47(12)	3774-3779	Liposomal Ampho	V	
188.	Lawn, S.	NWCL in returned travellers: treatment failures using intravenous sodium stibogluconate	Trans R Soc Trop Med Hyg.	2003		97	443-445	Antimon	V	X
189.	Lawn, S., Armstrong, M., Chilton, D., Whitty, C.	Electrocardiographic and biochemical adverse effects of sodium stibogluconate during treatment of CL and MCL among returning travellers	Trans R Soc Trop Med Hyg.	2006		1001264-269		Antimon	V	X
190.	Lawn, S., Whethman, J., Chiodini, P., Kanagalingam, J., Watson, J., Behrens, R., Lockwood, D.	New world mucosal and CL: an emerging health problem among British travellers	QualJM	2004	Dec	97(12)	781-8	Übersicht	A	
191.	Layegh, P., Yazdanpanah, M., Vosugh, E., Pezeshkpoor, F., Shakeri, M., Moghiman, T.	Efficacy of Azithromycin versus stemic meglumine antimoniate (Glucantime) in the treatment of CL	Am. J. Trop Med Hyg	2007		77(1)	99-101	Azithromycin	V	X
192.	Leibovici, V., Aram, H.	Cryotherapy in acute cutaneous Leishmaniasis	IntJDerm	1986	Sept	25 (7)	473-475	cryotherapy	V	X
193.	Lesho, E.	Nonhealing skin lesions in a sailor and a journalist returning from Iraq	Cleveland Clinic J Med	2005	Feb	72(2)	93-105	Klinik	V	
194.	Lessa, H., Machado, P.,	Sucessful treatment of refractory	Am J Trop	2001		65(2)	87-89	Pentoxifylline	V	X

	Lima, F. Cruz, A., Bacellar, O., Guerreiro, j., Carvalho, E.	MCL with pentoxifyline plus antimon	Med Hyg							
195.	Levine, N.,	CL treated with controlled localized heat	Arch Dermatol	1992	June	128	759-761	Heat	V	X
196.	Lightburn, E., Morand, J., Meynard, J., Kraemer, P., Chaudier, B., Pages, F., Garnotel, E., Patte, J., Banzet, S., Dampierre, H., Lepage, J., Morillon, M., Botin, J., Hovette, P., Chouc, C.	Management of ACL. Outcome apropos of 326 cases treated with high-dose pentamidine isethionate (Therapeutique des leishmanioses tegumentaires du nouveau monde experience a propos de 326 cas traites par isethionate de pantamidine a fortes doses)	Med Trop (Mars)	2003	Jan	63(1)	35-44	Pentamidine	V	X
197.	Llanos-Cuentas, A., Echevarria, J., Seas, C., Chang, E., Cruz, M., Alvarez, E., Rosales, E., Campos, P., Bryceson, A.	Parenteral aminosidine is not effective for Peruvian MCL	Am. J. Trop Med Hyg	2007		76(6)	1128-1131	Paromomycin	V	X
198.	Llanos-Cuentas, A., Echevarria, J., Cruz, M., La Rosa, A., Campos, P., Campos, M., Franke, E., Berman, J., Modabber, F., Marr, J.	Efficacy of Sodium stibogluconate alone and in Combination with Allopurinol for Treatment of Mucocutaneous Leishmaniasis	Clin Infect Dis	1997		25	677-84	Allopurinol plus Antimon vs Antimon	V	X
199.	Lobo, I., Soares, M., Correia, T., Freitas, L., Oliveira, M., Nakatani, M., Netto, E., Badaro, R., D'avid, J.	Heat therapy for CL elicits a systemic cytokine response similar to that of antimonial (Glucantime) therapy	Trans R Soc Trop Med Hyg.	2006		100	642-649	Heat vs Antimon	V	X
200.	Loiseau, P., Bories, C.	Recent strategies for the chemotherapy of visceral leishmaniasis	Current Opinion in Infect Dis	1999		12	559 - 564	Übersicht	V	
201.	Low-A Chee, R., Rose, P., Ridley, D.	An outbreak of CL in Guyana: epidemiology, clinical and laboratory aspects	Ann Trop Med Parasitol	1983		77 (3)	255-60	Pentamidine	V	X
202.	Lucas, C., Franke, E., Cachay, I., Tejada, A., Cruz, M., Kreutzer, R., Barker, D., McCann, S., Watts, D.	Geographic distribution and clinical description of Leishmaniasis in Peru	Am J Trop Med Hyg	1998		59(2)	312-317	Klinik	V	X

203.	Machado, P., Lessa, H., Guimaraes, L., Bang, H., Ho, J., Carvalho, E.	Oral Pentoxifylline combined with pentavalent antimony: a randomized trial for MCL	Clin Infect Dis	2007		44	788-793	Pentoxiphylline	V	X
204.	Machado-Coelho, G., Caiaffa, W., Genaro, O., Magahaes, P., Mayrink, W.	Risk facots for mucosal manifestation of American CL	Trans R Soc Trop Med Hyg.	2005		99	55-61	MCL	V	X
205.	Machado-Pinto, J., Pinto, J., da Costa, C., Genaro, O., Marques, M., Modabber, F., Mayrink, W.	Immunochemotherapy for CL: a controlled trial using killed Leishmania (L.) amazonensis vaccine plus antimonial	IntJDerm	2002		41	73-78	Immuno	V	X
206.	Macnair, A. et al	Hepatitis and ketoconazole therapy	Br Med J	1981		283	1058-1060	Azole Ketoconzol	F	
207.	Magill AJ, Grogl M, Gasser RA Jr, Sun W, Oster CN.	Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm	N Engl J Med	1993	May	13;328(19)	1383-7			
208.	Magill, A.	CL in the returning traveller	Infect Dis Clin N Am	2005		19	241-266	Übersicht	V	X
209.	Mahajan, V., Sharma, N.	Therapeutic options for CL	J Derm Treat	2007		18	97-104	Übersicht	V	X
210.	Markle, W., Makhoul, K.	CL: Recognition and Treatment	AmFamPhys	2004		69 (6)	1455-1460	Übersicht	V	X
211.	Marovich, M., Lira, R., Shepard, M., Fuchs, G., Kruetzer, R., Nutmann, T., Neva, F.	Leishmaniasis Recidivans Recurrence after 43 Years: A Clinical and Immunologic Report after Successful Treatment	Clin Infect Dis	2001	Oct	33	1076-1079		V	X
212.	Marques MJ, Volpini AC, Machado-Coelho GL, Machado-Pinto J, da Costa CA, Mayrink W, Genaro O, Romanha AJ.	Comparison of polymerase chain reaction with other laboratory methods for the diagnosis of American cutaneous leishmaniasis: diagnosis of cutaneous leishmaniasis by polymerase chain reaction.	Diagn Microbiol Infect Dis	2006	Jan	54(1)	37-43			
213.	Marsden P. et al	High continuous antimony therapy in two patients with unresponsive MCL	Trans R Soc Trop Med Hyg.	1985		34	710-713	Antimon	F	
214.	Martinez, S.	Allopurinol in the Treatment of ACL	N Engl J Med	1992	Mar	326	741-744	Allopurinol	V	
215.	Martinez, S., Looker, D., Berens, R., Marr, J.	The synergistic action of pyrazolopyrimidines and pentavalent antimony against	Am J Trop Med Hyg	1988	Sep	39(3)	250-255	Antimon	V	X

		Leishmania donovani and L. braziliensis								
216.	Matlashewski, G.	Leishmania infection and virulence	Med Microbiol Immunol	2001		190	37-42		V	
217.	McBride MO, Linney M, Davidson RN, Weber JN.	Pancreatic necrosis following treatment of leishmaniasis with sodium stibogluconate.	Clin Infect Dis	1995	:	21 (3)	710.	Antimon	V	
218.	McMahon-Pratt, D., Alexander, J.	Does the leishmania major paradigm of pathogenesis and protection hold for the NWCL or the visceral disease?	Imun Rev	2004		201	206-224	Pathogenese	V	X
219.	Mebrahtu Y, Lawyer P, Githure J, Were JB, Muigai R, Hendricks L, Leeuwenburg J, Koech D, Roberts C	Visceral leishmaniasis unresponsive to pentostam caused by Leishmania tropica in Kenya	Am J Trop Med Hyg	1989	Sep	41	289-294			
220.	Mendonca, M.	Persistence of Leishmania Parasites in Scars after Clinical Cure of American CL: Is There a Sterile Cure?	J Infect Dis	2004	Mar	189	1018-23		V	X
221.	Meyerhoff, A.	U.S. Food and Drug Administration Approval of AmBisome (Liposomal Amphotericin B) for Treatment of Visceral Leishmaniasis	Clin Infect Dis	1999		28	42-8	Liposomal Ampho	V	
222.	Michalick, M.	Genero Leishmania	Buchkapitel				31-72	Übersicht	V	
223.	Minodier, P., Noel, G., Blanc, P., Uters, P., Retornaz, K., Garnier, J.	Management of CL in adults and children	Med Trop (Mars)	2005	Nov	65(5)	487-95	Übersicht	V	X
224.	Minodier, P., Parola, P.	CL treatment	Trav Med Inf Dis	2007		5	150-158	Übersicht	V	X
225.	Miranda-Verástegui, C., Llanos-Cuentas, A., Arévalo, I., Ward, B., Matlashewski, G.	Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of CL in Peru	Clin Infect Dis	2005	May	40	1395-1403	Imiquimod vs Antimon	V	X
226.	Mirzabeigi, M., Farooq, U., Baraniak, S., Dowdy, L.,	Reactivation of dormant CL infection in a kidney transplant	J Cut Path	2006		33	701-704		V	X

	Ciancio, G., Vincek, V.	patient								
227.	Modabber, F.	Experiences with vaccines against CL: of men and mice	Parasitology	1989		98	49-60		V	
228.	Modabber, F., Buffet, P., Torreele, E., Milon, G., Croft, S.	Consultative meeting to develop a strategy for treatment of CL. Review. Institute Pasteur, Paris. 13-15 June, 2006	Kinetoplastid Biology and Disease	2006			1-24	Übersicht	V	X
229.	Mohebali, M., Fotouhi, A., Hooshmand, B., Zarei, Z., Akhouni, B., Rahnama, A., Razaghian, A., Kabir, M., Nadim, A.	Comparison of Miltefosine and meglumine antimoniate for the treatment of zoonotic CL (ZCL) by a randomized clinical trial in Iran	Acta Tropica	2007		103(1)	33-40	Miltefosine	V	X
230.	Momeni AZ, Shafiei A, Emamjoei M, Aminjavaheri M, Momeni A	Azithromycin is not effective in the treatment of old world cutaneous leishmaniasis	Eur J Dermatol	2006	Nov-Dec	16(6)	701-702	Azithromycin	V	X
231.	Momeni, A., Aminjavaheri, M.	Successful treatment of non – healing cases of CL, using a combination of meglumine antimoniate plus allopurinol	EurJDerm	2003	Feb	13(1)	40-3	Allopurinol plus Antimon	V	
232.	Momeni, A., Aminjavaheri, M.	Treatment of recurrent CL	IntJDerm	1995	Feb	34(2)	129-133	Allopurinol plus Antimon	V	X
233.	Momeni, A., Aminjavaheri, M., Omidghaemi, M.	Treatment of CL with Ketoconazole cream	J Derm Treat	2003		14	26-29	Azole	V	X
234.	Momeni, A., Jalayer, T., Emamjomeh, M., Bashardost, N., Ghassemi, R., Meghdadi, M., Javadi, A., Aminjavaheri, M.,	Treatment of CL with itraconazole. Randomized double – blind study.	Arch Dermatol	1996	Jul	132(7)	784-6	Azole Itraconazol	A	
235.	Momeni, A., Reiszadae, M., Aminjavaheri, M.	Treatment of CL with the combination of allopurinol and low-dose meglumine antimoniate	IntJDerm	2002	Jul	41(7)	441-443	Allopurinol plus Antimon	V	X
236.	Moreira, S.	Therapeutic trial in experimental tegumentary leishmaniasis caused by <i>Leishmania (Leishmania) amazonensis</i> . A comparative study between mefloquine and aminosidine	Rev Soc Bras Med Trop	2000	Jul-Aug	33(4)	377-382	Paromomycin iv vs Mefloquine	V	X

237.	Morelli, P.	Itraconazol can be effective in the Treatment of Sporotrichoid Leishmaniasis	J Travel Med	2004		11	328-330	Azole Itraconazol	V	X
238.	Morgan, D., Guimaraes, L., Machado, P. et al.	CL during Pregnancy: Exuberant Lesions and potential fetal complications	ClinInfDis	2007	Aug	45	478-482	Schwangerschaft	V	X
239.	Morizot, G., Delgiudice, P., Caumes, E., Laffitte, E., Marty, P., Dupuy, A., Sarfati, C., et.al.	Healing of OWCL in travellers treated with Floconazole: drug effect or sponatenous evolution?	Am J Trop Med Hyg	2007		76(1)	48-52	Azole	V	X
240.	Morris-Jones, S.	Medical Mystera: Painless Ulcers-The Answer	N Engl J Med	2004	May	350 (22)	2313-2314	Klinik	V	
241.	Mujtaba, G.	Weekly vs. fortnightly intralesional meglumine antimoniate in CL	IntJDerm	1999	Aug	38(8)	607-	IL Antimon	V	X
242.	Murray, H.	Advances in Leishmaniasis	Lancet	2005	Oct	366	1561-1577	Übersicht	V	X
243.	Murray,H.	Treatment of visceral leishmaniasis in 2004	Am J Trop Med Hyg	2004		71(6)	787-794	Übersicht	V	X
244.	Musa AM et al.	Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL).	Ann Trop Med Parasitol	2005		99	563-9	Liposomal Ampho	A	
245.	Myler, P.	The Leishmania genome project : new insights into gene organization and function	Med Microbiol Immunol	2001		190	9-12	Übersicht	V	
246.	Nacher, M., Carme, B., Sainte Marie, D., Couppie, P., Clyti, E., Guibert, P., Pradinaud, R.	Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of CL in French Guiana	Ann Trop Med Parasitol	2001		95(4)	331-336	Pentamidine	V	X
247.	Nagaty, I.	Treatment of CL Patients with pentostam via intraleasional infiltration	J Egypt Soc Parasitol	2000	April	30(1)	177-182	II Antimon vs Antimon	V	
248.	Nakayama, H., Loiseau, P., Bories, C., Torres de Ortiz, S., Schinini, A., Serna, E., Rojas de Arias, A., Fakhfakh, M., Franck, X.,	Eficacy of orally adminstered 2 – substituted quinolines in experimental murine cutaneous and visceral leishmaniasis	Antimicrob Agents Chemother	2005	Dec	49(12)	4950-6	experimental	A	

	Figadere, B., Hocquemiller, R., Fournet, A.									
249.	Nassiri, K., Firooz, A., Khamesipour, A., Nilforoushzadeh, M., Hejazi, H., Bouzari, N., Dowlati, Y	A randomized, double – blind, placebo controlled clinical trial of itraconazole in the treatment of CL	JEADV	2005		19	80-83	Azole Itraconazol	V	
250.	Navin T.	Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating CL in Guatemala	J Infect Dis	1992	Mar	165(3)	528-34	Azole Ketoconazol vs Antimon	A	
251.	Navin T.	Placebo-controlled clinical of meglumine antimonate (glucantime vs. localized controlled heat in the treatment of CL in Guatemala	Am J Trop Med Hyg.	1990	Jan	42(1)	43-50	Heat vs Antimon	V	X
252.	Neal, R., Allen, S., McCoy, N., Olliaro, P., Croft, S.	The sensitivity of Leishmania spezies to aminosidine	J Antimicrob Chem	1995		35	577-584	Paromomycin	V	X
253.	Neal, R., Murphy, A., Olliaro, P., Croft, S.	Aminosidine ointments for the treatment of experimental CL	Trans R Soc Trop Med Hyg.	1994		88	223-225	Paromomycin	V	X
254.	Netto, E., Marsden, P., Llanos-Cuetas, E., Costa, J., Cuba, C., Barreto, A., Badaro, R., Johnson, W., Jones, T.	Long – term follow - up of patients with Leishmania (Viannia) braziliensis infection and treated with Glucantime	Trans R Soc Trop Med Hyg.	1990		84	367-370	Antimon	V	X
255.	Neva, F., Petersen, E., Corsey, R., Bogaert, H., Martinez, D.	Observations on local heat treatment for CL	Am. J. Trop Med Hyg	1984		33(5)	800-804	Thermotherapy	V	X
256.	Neva, F., Ponce, C., Ponce, E., Kreutzer, R., Modabber, F., Olliaro, P.	Non – ulcerative CL in Honduras fails to respond to topical paromomycin	Trans R Soc Trop Med Hyg.	1997		91	473-475	Paromomycin	V	X
257.	Norton SA, Frankenburg S, Klaus SN.	Cutaneous leishmaniasis acquired during military service in the Middle East.	Arch Dermatol.	1992	Jan	128(1)	83-7			
258.	Ojha, R., Cervantes, D., Fischbach, L.	Oral pentoxifylline and pentavalent antimony for treatment of Leishmaniasis: promising but	Clin Infect Dis	2007	Oct	45	1104-1105	Pentoxifylline	V	X

		inconclusive evidence of superiority, compared with antimony monotherapy								
259.	Oliveira – Neto, M.	High and Low Doses of Antimony in American CL. A Five Years Follow – up Study of 15 Patients	Mem Inst Oswaldo Cruz	1996	Mar - Apr	91(2)	207-209	Antimon	V	
260.	Oliveira – Neto, M.	Intralesional therapy of American CL with pentavalent antimony in Rio de Janeiro, Brazil – an area of Leishmania braziliensis transmission	IntJDerm	1997	Jun	36(6)	463-8	IL Antimon	V	X
261.	Oliveira de Sá, T.	Action of pentoxifylline on experimental cutaneous leishmaniasis due to Leishmania (Leishmania) amazonensis.	Mem Inst Oswaldo Cruz	2000	Jul - Aug	95(4)	477-482	Pentoxifylline	V	X
262.	Oliveira –Neto, M.,	Tratamentos antimoniais da leishmaniose	Rev Soc Bras Med Trop	2005	Sep-Okt	38(5)	446-447	Antimon	V	X
263.	Oliveira-Neto, M., da Silva Mattos, M.	An alternative antimonial schedule to be used in CL when high doses of antimony are undesirable	Rev Soc Bras Med Trop	2006	Jul-Aug	39 (4)	323-326	Antimon	V	X
264.	Oliveira-Neto, M., Schubach, A., Mattos, M., Goncalves, S., Pirmez, C.	Intralesional therapy of ACL with pentavalent antimony in Rio de Janeiro, Brazil – an area of Leishmania (V.) braziliensis transmission	IntJDerm	1997		36	463-468	Intralesional	V	X
265.	On,J.	Topical Chemotherapy of CL	Parasitology Today	1988		4(3)	76-81	Übersicht	V	
266.	Oster C. et al	ACL: a comparison of three sodium stibogluconate treatment schedules	Am. J. Trop Med Hyg	1985		34	856-860	Antimon	F	
267.	Ozgoztasi,O.,Baydar,I.	A randomized clinical trial of topical paromomycin versus oral ketoconazole for treating CL in Turkey	IntJDerm	1997	Jan	36(1)	61-3	Azole Ketoconazol vs Paromomycin	V	X
268.	Palacios, R., Osorio, L., Grajales, L., Ochoa, M.	Treatment failure in children in a randomized clinical treat with 10 and 20 days of Meglumine Antimoniate for CL due to	Am J. Trop Med Hyg	2001		64(3,4)	187-193	Antimon	V	X

		Leishmania Viannia species								
269.	Panagiotopoulos, A., Stavropoulos, P., Hasapi, V., Papakonstantinou, A., Petridis, A., Katsambas, A.	Treatment of CL with cryosurgery	IntJDerm	2005	Sep	44(9)	749-52	Cryotherapy	V	X
270.	Paradisi A et al.	Atypical multifocal cutaneous leishmaniasis in an immunocompetent patient treated by liposomal amphotericin.	Br J Infect	2005		51	261-4	Liposomal Ampho	V	X
271.	Passos, V.	Leishmaniose tegumentar na Regiao Metropolitana de Belo Horizonte: aspectos clinicos, laboratoriais terapeuticos e evolutivos (1989-1995)	Rev Soc Bras Med Trop	2001	Jan-Feb	34(1)	5-12	Übersicht	V	X
272.	Pearson, R.	Leishmania Species: VL, CL and MCL	Infect Dis Etiolog Agents				2831-2845	Übersicht	V	
273.	Ponce C, Ponce E, Morrison A, Cruz A, Kreutzer R, McMahon-Pratt D, Neva F	Leishmania donovani chagasi: new clinical variant of CL in Honduras	Lancet	1991	Jan	12;337 (8733)	67-70			
274.	Pradinaud, R.	CL	Society for Dermatol in the Trop	2005	Okt			Übersicht	V	
275.	Prata A, Silva-Vergara ML, Costa L, Rocha A, Krolewiecki A, Silva JC, de Paula EV, Pimenta Junior FG, Giraldo LE	Efficacy of azithromycin in the treatment of cutaneous leishmaniasis.	Rev Soc Bras Med Trop	2003	Jan-Feb	36(1)	65-69	Azithromycin	V	X
276.	Rahman, S., Bari, A., Mumtaz, N.	Miltefosine in cutaneous leishmaniasis	J Coll Physicians Surg Pak	2007	Mar	17(3)	132-135	Miltefosine	V	X
277.	Rajab M.	Intralesional Treatment of CL with Sodium Stibogluconate Antimony	IntJDerm	1993	Aug	32(8)	610-612	IL Antimon	V	X
278.	Ramírez, J., Agudelo, S., Muskus, C., Alzate, J., Berberich, C., Barker, D., Vélez, I.	The method used to sample ulcers influences the diagnosis of CL	Trans R Soc Trop Med Hyg.	2002		S1	169-171	Diagnostik	V	X
279.	Rapp C et al.	Liposomal amphotericin B	Bull Soc	2003		96	209-11	Liposomal		

		treatment of cutaneous leishmaniasis contracted in Djibouti and resistant to meglumine antimoniate.	Pathol Exot					Ampho		
280.	Rawlins, S.	ACL in Guyana, South America	Ann Trop Med Parasitol	2001		95(3)	245-251		V	X
281.	Reithinger, R.	Efficacy of Thermotherapy to Treat CL Caused by <i>Leishmania tropica</i> in Kabul, Afghanistan: A Randomized, Controlled Trial	Clin Infect Dis	2005	April	40	1148-1158	Heat	V	X
282.	Reithinger, R., Coleman, P.	Treating CL patients in Kabul, Afghanistan: cost-effectiveness of an operational program in a complex emergency setting	BMC	2007		7	1-9	Übersicht	V	X
283.	Reithinger, R., Dujardin, J., Louzir, H., Pirmez, C., Alexander, B., Brooker, S.	CL	TLID	2007	Sept	7	581-596	Übersicht	V	X
284.	Reyburn, H.	The prolonged epidemic of anthroponotic CL in Kabul, Afghanistan: 'bringing down the neighbourhood	Trans R Soc Trop Med Hyg.	2003		97	170-176		V	X
285.	Ribeiro, C., Sampaio, J., Cardoso, D., Sampaio, R.	A comparative study between the efficacy of pentamidine iosthionate given in three dosis for a week and N-methyl-glucamine in a dose of 20mgSbV/day for 20 days to treat CL	Rev Soc Bras Med Trop	2003	Mai-Jun	36(3)	365-371	Pentamidine vs Antimon	V	X
286.	Rijal, S., Chappius, F., Singh, R., Bovier, P., Acharya, B., Karki, B., Das, M., Desjeux, P., Loutan, L., Koirala, S.	Treatment of visceral leishmaniasis in south – eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline	Trans R Soc Trop Med Hyg.	2003		97	350-354	Antimon	V	X
287.	Rijal, S., Chappuis, S., Singh, R., Boelaert, M., Loutan, L., Koirala, S.	Sodium stibogluconate cardiotoxicity and safety of generics	Trans R Soc Trop Med Hyg.	2003		97	597-598	Antimon	V	X
288.	Ritmeijer, K., Dejenie, A., Assefa, Y., Hundie, T., Mesure, J., Boots, G., den	A comparison of Miltefosine and sodium stibogluconate for treatment of VL in an Ethiopian	CID	2006		43	357-364	Miltefosine	V	X

	Boer, M., Davidson, R.	population with high prevalence of HIV infection								
289.	Robert, W., Rainley, P.	Antileishmanial activity of sodium stibogluconate fractions	Antimicrob Agents Chemother	1993	Sept	37 (9)	1842-1846	Antimon	V	X
290.	Roberts, M.	Current understandings on the immunology of leishmaniasis and recent developments in prevention and treatment	Br Med Bull	2006	July	75-76	115-130	Übersicht	V	X
291.	Robinson RJ, Agudelo S, Muskus C, Alzate JF, Berberich C, Barker DC, Velez ID.	The method used to sample ulcers influences the diagnosis of cutaneous leishmaniasis.	Trans R Soc Trop Med Hyg.	2002	Apr	96 Suppl 1	S169-71			
292.	Rojas R, Valderrama L, Valderrama M, Varona MX, Ouellette M, Saravia NG.	Resistance to antimony and treatment failure in human Leishmania (Viannia) infection.	J Infect Dis.	2006	May	15;193(10)	1375-83	Antimon	V	X
293.	Romero, G.	Comparison of CL due to <i>Leishmania (Viannia) Braziliensis</i> and <i>L. (V.) Guyanensis</i> in Brazil: Therapeutic response to Meglumine Antimoniate	Am J. Trop Med Hyg.	2001		65(5)	456-465	Antimon	V	X
294.	Romero, G., Lessa, H., Orge, M., Macedo, V., Marsden, P.	Tratamento da leishmaniose mucosa com sulfato de aminosidine: resultados de dois anos de acompanhamento	Rev Soc Bras Med Trop	1998	Nov-Dec	31(6)	511-516	Paromomycin	V	X
295.	Roussel, M., Nacher, M., Frémont, G., Rotureau, B., Clyti, E., Sainte-Marie, D., Carme, B., Pradinaud, R., Couppie, P.	Comparison between one and two injections of pentamidine isethionate, at 7mg/kg in each injections, in the treatment of CL in French Guiana	Ann Trop Med Parasitol	2006		100 (4)	307-314	Pentamidine	V	X
296.	Sacks, D., Barral, A., Neva, F.	Thermosensitivity patterns of OWCL vs NWCL of Leishmania growing within mouse peritoneal macrophages in vitro	Am. J. Trop. Med Hyg	1993		32(2)	300-304	Heat	V	X
297.	Sacks DL, Kenney RT, Kreutzer RD, Jaffe CL, Gupta AK, Sharma MC, Sinha SP, Neva FA, Saran	Indian kala-azar caused by <i>Leishmania tropica</i>	Lancet	1995	Apr:	15;345 (8955)	959-61			

	R.									
298.	Sadeghian, G., Nilforoushzadeh, M.	Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of CL	IntJDerm	2006		45	819-821	Pentoxifylline plus Antimon	V	X
299.	Sadeghian, G., Nilforoushzadeh, M., Itaji, F.	Efficacy of local heat therapy by radiofrequency in the treatment of CL, comparison with intraleisional injection of meglumine antimoniate	ClinDerm	2007		32	371-374	Thermotherapy	V	X
300.	Saenz, R., Paz, H., Bermann, J.	Efficacy of ketoconazole against Leishmania braziliensis panamensis CL	Am J Med	1990	Aug	89 (2)	147-55	Azole Ketoconazol	V	
301.	Saenz, R., Paz, H., Johnson, C., Marr, J., Nelson, D., Pattishall, K., Rogers, M.	Treatment of ACL with orally administered allopurinol riboside	J Infect Dis	1989	Jul	160(1)	153-8	Allopurinol	A	
302.	Saldanha, A..	Estudo comparativo entre estibogluconato de sodio BP 88R e antimoniato de meglumina no tratamento da leishmaniose cutanea: I. Eficacia e seguranca	Rev Soc Bras Med Trop	1999	Jul-Aug	32(4)	383-387	Antimon	V	X
303.	Salman SM, Rubeiz NG, Kibbi AG.	Cutaneous leishmaniasis: clinical features and diagnosis	Clinics in Dermatol	1999	May-Jun	17(3):	291-6.			
304.	Salmanpour, R.	Comparative study of the efficacy of oral ketoconazole with intra – lesional meglumine antimoniate (Glucantime) for the treatment of CL	J Derma Treat	2001	Sep	12(3)	159-162	Azole Ketoconazoil vs IL Antimon	A	
305.	Salmanpour, R. Razmavar, M., Abtahi, N.	Comparison of intra – lesional meglumine antimoniate, cryotherapy and their combination in the treatment of CL	IntJDerm	2006		45	1115-1116	Cryotherapy	V	X
306.	Sampaio R. et al.	Treatment of the mucosal form of leishmaniasis without response to glucantime, with liposomal amphotericin B.	Rev Soc Bras Med Trop	1997		30	125-8	Liposomal Ampho	V	X
307.										
308.	Nonata R., Sampaio,R.,	Mucosal leishmainiasis	Trans R Soc	1997		91	77	Liposomal	V	X

	Marsden, P.	unresponsive to glucantime therapy successful treated with AmBisome	Trop Med Hyg.					Ampho		
309.	Sands, M., Kron, M., Brown, R.	Pentamidine: A Review	Rev Inf Dis	1995	Sep	7 (5)	625-634	Pentamidine	V	X
310.	Santos, I., Dos- Santos, I., Montenegro, D., Lemos, E., Pereira, T.	Uso do itraconazol em 26 pacientes portadores de leishmaniose tegumentar americana	Ann Bras Dermatol	1995	Mar - Apr	70(2)	103-107	Azole Itraconazol	V	
311.	Santos, J.	Antimony plus Recombinant Human Granulocyte-Macrophage Colony-StimulatingFactor Applied Topically in Low Doses Enhances Healing of CL Ulcers: A Randomized,Double-Blind,Placebo-Controlled Study	J Infect Dis	2004		190	1793-6	HGMCSF plus Antimon	V	X
312.	Schallreuter, K., Lemke, K.	Erfolgreiche topische Behandlung der chronischen CL mit Paromomycinsufat (15%) und Methylbenzethoniumchlorid (12%)	Hautarzt	1994		45	783-786	Paromomycin	V	
313.	Schmidt-Ott, R.	Topical treatment with hexadecylphosphocholine (Miltex) efficiently reduces parasite burden in experimental CL	Trans R Soc Trop Med Hyg.	1999		93	85-90	Miltefosine	V	X
314.	Schriefer A, Schriefer AL, Goes-Neto A, Guimaraes LH, Carvalho LP, Almeida RP, Machado PR, Lessa HA, de Jesus AR, Riley LW, Carvalho EM.	Multiclonal Leishmania braziliensis population structure and its clinical implication in a region of endemicity for American tegumentary leishmaniasis	Infect. Immun	2004	Jan	72(1)	508-14			
315.	Schubach, A., Marzochi, K., Moreira, J. et al	Retrospective study of 151 patients with CL treated with meglumine antimoniate	Rev Soc Bras Med Trop	2005	Mai-Jun	38(3)	213-217	Antimon	V	X
316.	Schubach, A., Haddad, F., Pae-Oliveira Neto, M et al.	Detection of Leishmania DNA by polymerase chain reaction in scars of treated human patients	J Infect Dis	1998		178	911-914		V	X
317.	Schwartz, E.	NWCL in travellers	Lancet Inf Dis	2006		6	342-49	Übersicht	V	X

318.	Scope, A., Trau, H., Bakon, M., Yarom, N., Nasereddin, A.	Imported MCL in a traveler	Clin Infect Dis	2003	Sept	37	E83-e87	MCL	V	X
319.	Scott, J	Aminosidine (paromomycin) in the treatment of Leishmaniasis imported into the UK	Trans R Soc Trop Med Hyg.	1992		86	617-619	Paromomycin	V	X
320.	Seaton, R., Morrison, J., Man, I., Watson, J., Nathwani, D.	Out – patient parenteral antimicrobial therapy – a viable option for the management of CL	QualJM	1999		92	659-667		V	
321.	Seeberger, J., Daoud, S., Pammer, J.	Transient effect of topical treatment of CL with imiquimod	IntJDerm	2003		42	576-579	Imiquimod	V	X
322.	Shani-Adir, A.; Kamil, S.; Rozenman, D. et al.	Leishmania tropica in northern Israel: A clinical overview of an emerging focus	J Am Acad Dermatol	2005		53(5)	810-815	Paromomycin vs Antimon IL vs Antimon i.m.	V	X
323.	Shapira, M.	Post transcriptional control of gene expression in Leishmania	Med Microbiol Immunol	2001		190	23-26	Immunologie	V	
324.	Sharma, N.	Localized CL due to <i>Leishmania donovani</i> and <i>Leishmania tropica</i> : Preliminary findings of the study of 161 new cases from a new Endemic focus in Himachal Pradesh, India	Am J Trop Med Hyg	2005		72(6)	819-824	Klinik	V	X
325.	Sharquie, K.	Intralesional therapy of CL with sodium stiboglucante antimony	Br J Derm	1988	Jul	119(1)	53-57	IL Antimon	F	
326.	Sharquie, K.	Oral zinc sulphate in the treatment of acute CL	Clinical Dermatology	2001		26	21-26	Zinc	V	
327.	Sharquie, K.	A comparative controlled trial of intralesionally-administered zinc sulphate, hypertonic sodium chloride and pentavalent antimony compound against acute CL	Clin Exp Dermatol	1997	Jul	22(4)	169-73	Zinc IL vs Antimon vs NaCl	A	
328.	Sharquie, K., al-Hamamy, H., el -Yassin, D.	Treatment of CL by direct current electrotherapy; the Baghdadin device.	J Dermatol	1998	Apr	25(4)	234-7	Heat	V	
329.	Shazad, B., Abbaszadeh, B., Khamesipour, A.	Comparison of topical paromomycin sulfate (twice/day)	EurJDerm	2005	March-April	15(2)	85-87	Paromomycin vs IL Antimon	V	X

		intralesional meglumine antimoniate for the treatment of CL caused by <i>L. major</i>								
329a	Shaw J.	The leishmaniasis--survival and expansion in a changing world. A mini-review.	Mem Inst Oswaldo Cruz.	2007	Aug	102(5)	541-7	Übersicht		
330.	Silva, S., Rueda, L., López, M., Vélez, I., Rueda-Clausen, C., Smith, D., Munoz, G., Mosquera, H., Silva, F., Buitrago, A., Díaz, H., López-Jaramillo, P.	Double-blind, randomized controlled trial, to evaluate the effectiveness of a controlled nitric oxide releasing patch versus meglumine antimonite in the treatment of CL	Trials	2006	May	7 (14)	1-11	Nitric oxide vs Antimon	V	X
331.	Silveira, F., Lainson, R., Corbett, C.	Clinical and immunopathological spectrum of American cutaneous leishmaniasis with special reference to the disease in Amazonian Brazil: a review	Mem Inst Oswaldo Cruz	2004	May	99(3):2	39-51	Übersicht	V	X
332.	Sindermann, H., Engel, J.	Development of Miltefosine as an oral treatment for Leishmaniasis	Trans R Soc Trop Med Hyg.	2006		100S	S17-20	Miltefosine	V	X
333.	Sindermann, H., Engel, K., Fischer, C., Bommer, W	Oral Miltefosine for Leishmaniasis in Immunocompromised Patients: Compassionate Use in 39 Patients with HIV Infection	Clin Infect Dis	2004	Nov	39	1520-1523	Miltefosine	V	X
334.	Singh, R., Sundar, S.	Failure of Ketoconazole treatment in CL	IntJDerm	1995	Feb	34	120-121	Azole Ketoconazol	V	X
335.	Siriwardana HV, Noyes HA, Beeching NJ, Chance ML, Karunaweera ND, Bates PA.	Leishmania donovani and cutaneous leishmaniasis, Sri Lanka	Emerg Infect Dis	2007	Mar	13(3)	476-8			
336.	Solomon, M., Baum, S., Barziliai, A.	Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis.	J Am Acad Dermatol	2007		Feb	2	Liposomal Ampho	V	
337.	Soto, J.	Short Report: Efficacy of Pentavalent Antimony for Treatment of Colombian CL	Am. J. Trop Med Hyg	2005		72(4)	421-422	Antimon	V	X
338.	Soto, J.	Treatment of ACL with	Clin Infect	2001	Oct	33(7)	1086	Miltefosine	V	X

		Miltefosine, an Oral Agent	Dis							
339.	Soto, J., Arana, B., Toledo, J. et al	Miltefosine for NWCL	Clin Infect Dis	2004	May	38	1266-1272	Miltefosine	V	X
340.	Soto, J., Berman, J.	Treatment of NWCL with Miltefosine	Trans R Soc Trop Med Hyg.	2006		100S	S34-40	Miltefosine	V	X
341.	Soto, J., Buffet, P., Grogl, M., Berman, J.	Successful treatment of Colombian CL with four injections of pentamidine	Am J Trop Med Hyg	1994		50(1)	107-111	Pentamidine	V	X
342.	Soto, J., Fuya, P., Herrera, R., Berman, J.	Topical Paromomycin / Methylbenzethonium Chloride Plus Parenteral Meglumine Antimonate as Treatment for ACL: Controlled study	Clin Infect Dis	1998		26	56-8	Paromomycin vs Antimon	V	X
343.	Soto, J., Hernandez, N., Mejia, H., Grogl, M., Berman, J.	Successful Treatment of New World CL with a Combination of Topical Paromomycin/Methylbenzethonium Chloride and Injectable Meglumine Antimonate	Clin Infect Dis	1995		20	47-51	Paromomycin plus IL Antimon	V	
344.	Soto, J., Soto, P.	Miltefosine: oral treatment of leishmaniasis	Expert Rev. Anti Infect. Ther.	2006		4 (2)	177-85	Miltefosine	V	
345.	Soto, J., Toledo, J., Gutierrez, P., Arboleda, M., Nicholls, R., Padilla, J., Berman, J., English, C., Grogl, M.	Treatment of CL with a topical antileishmanial drug (WR279396): Phase 2 pilot study	Am J Trop Med Hyg	2002		66 (2)	147-151	Experimental	V	X
346.	Soto, J., Toledo, J., Valda, et al.	Treatment of bolivian MCL with Miltefosine	Clin Infect Dis	2007	Febr	44	350-356	Miltefosine	V	X
347.	Soto-Mancipe, J., Grogl, M., Berman, J.	Evaluation of pentamidine for the treatment of CL in Columbia	Clin Infect Dis	1993	Mar	16(3)	417-25	Pentamidine	V	X
348.	Sriwardena, H., Udagedara, C., Karunaweera N.	Clinical features, risk factors and efficacy of cryotherapy in CL in Sri Lanka	Ceylon Med J	2003	Mar	48 (1)	10-12	Cryotherapy	A	
349.	Stanimirovic, A.	Treatment of CL with 20% paromomycin ointment	J Eur Acad Dermatol Venerol	1999		13	214-217	Paromomycin	V	

350.	Stojiljkovic, I., Evavold, B, Kumar, V.	Antimicrobial properties of porphyrins	Expert Opin Investig Drugs	2001.		10	309-320.	PDT		
351.	Stojkovic, M., Junghanss, T., Krause, E., Davidson, R.	First case of OWCL treated with miltefosine	IntJDerm	2007		46	385-387	Miltefosine	V	X
352.	Storer, E.	CL in Afghani refugees	Australasian J of Derma	2005	May	46(2)	80		A	
353.	Sundar, S.	Failure of Pentavalent Antimony in VL in India: Report from the Center of the Indian Epidemic	Clin Infect Dis	2000	Oct	31	1104-7	Antimon	V	
354.	Sundar, S.	Short – Course of Oral Miltefosine for Treatment of VL	Clin Infect Dis	2001	Oct	31	1110-3	Miltefosine VL	V	
355.	Sundar, S.	Oral Miltefosine for Indian VL	N Engl J Med	2002	Nov	347(22)	1739-1746	Miltefosine VL	V	X
356.	Sundar, S.	Treatment of VL	Med Microbiol Immunol	2001	Nov	190(1-2)	89-92	Übersicht	A	
357.	Sundar, S.	Drug resistance in Indian VL	Trop Med Intern Health	2001	Nov	6(11)	849-54	VL	V	
358.	Sundar, S., Agrawal, G., Rai, M., Makharia, M., Murray, H.	Treatment of Indian VL with single or daily infusions of low dose liposomal amphotericin B: randomised trial	BMJ	2001	Aug	323	419-422	Liposomal Ampho	V	
359.	Sundar, S., Gupta, L., Makharia, M., Singh, M.	Oral Treatment of visceral leishmaniasis with Miltefosine	Ann Trop Med Parasitol	1999		93(6)	589-597	Miltefosine VL	V	
360.	Sundar, S., Jha, T., Thakur, C., Bhattacharya, S., Rai, M.	Oral miltefosine for the treatment of indian VL	Trans R Soc Trop Med Hyg.	2006		100S	S26-33	Miltefosine VL	V	X
361.	Sundar, S., Jha, T., Thakur, C., Sinha, P.	Injectable paromomycin for VL in India	N Engl J Med	2007	June	356(25)	2571-81	Paromomycin	V	X
362.	Sundar, S., Mehta, H., Suresh, A., Singh, S., Rai, M., Murray, H.	Amphotericin B Treatment for Indian VL: Conventional versus Lipid Formulations	Clin Infect Dis	2004		38	377-83	Liposomal Ampho	V	
363.	Sundar, S., Thakur, C., Bachmann, P., Karbwang, J., Fischer, C., Voss, A., Berman, J.	Miltefosine, an oral Agent, for the Treatment of Indian VL	N Engl J Med	1999	Dec	341(24)	1795-1800	Miltefosine VL	V	X
364.	Sundar, S., Rosenkaimer, F., Makharia, M., Goyal, A., Mandal	Trial of oral Miltefosine for visceral leishmaniasis	Lancet	1998	Dec	352	1821-1823	Miltefosine VL	V	X

	,A.,Voss,A.,Hilgard,P.,Murray,H.									
365.	Talhari, S., Sardinha, J., Schettini, A., Arias, J., Naiff, R.	Tratamento da leishmaniose tegumentar americana	Ann Bras Dermatol	1985		60(6)	361-364		V	
366.	Talhari,S.	A comparative Five – Doses Trial of Isothionate of pentamidine in patients with ACL	The leishmaniasis	1984		27		Pentamidine	V	
367.	Tallab, M.	CL: Schedules for intralesional Treatment with Sodium Stibogluconate	IntJDerm	1996	Aug	35(8)	594-597	IL Antimon	V	X
368.	Thakur, C.	Treatment of VL (kala – azar) with aminosidine (paromomycin)-antimonial combinations, a pilot study in Bihar, India	Trans R Soc Trop Med Hyg.	1992		86	615-616	Paromomycin plus antimon	V	X
369.	Thakur,C.	Sodium antimony gluconate, amphotericin, and myocardial damage	Lancet	1998	Jun	351	1928-1929	Antimon Ampho	V	
370.	Thiel, M.	Comparative proteome analysis of <i>Leishmania donovani</i> at different stages of transformations from promastigotes to amastigotes	Med Microbiol Immunol	2001		190	33-36		V	
371.	Toledo, V.	Immunochemotherapy in ACL: Immunological Aspects before and after Treatment	Mem Inst Oswaldo Cruz	2001	Jan	96(1)	89-98	Immunologie	V	
372.	Torre-Cisneros J et al.	Successful treatment of antimony-resistant cutaneous leishmaniasis with liposomal amphotericin B.	Clin Infect Dis	1994		18(6)	1024-5	Liposomal Ampho		
373.	Toubiana, J., Armengaud, J., Dupouy, C., Gendrel, D.	Oral fluconazole treatment for extensive CL in an 11-year-old child	Ped Infect Dis	2006	Nov	25(11)	1083-1084	Azole Fluconazole	A	
374.	Tuon, F., Amato, V., Floeter-Winter, L., de Andrade, R., Neto, V., Siqueira, F., Shikanai-Yasuda, M.	CL reactivation 2 years after treatment caused by systemic corticosteroids – first report	IntJDerm	2007		46	628-630		V	X
375.	Turetz, M., Machado, P.,	Disseminated leishmaniasis: a new	Bra J Infect	2002		186	1829-1834	Diss CL	A	

	Ko, A., Alves, F., Bittencourt, A., Almeida, R., Mobashery, N., Johnson, W., Carvalho, E.	and emerging form of leishmaniasis observed in northeastern 186:1829-1834.	Dis							
376.	Uzun, S.	Clinical features, epidemiology, and efficacy and safety of intralesional antimony treatment of CL: recent experience in Turkey	J Parasitol	2004	Aug	90(4)	853-859	IL antimon	V	X
377.	Valdir, S.	Use of Itraconazole in the Treatment of MCL: A Pilot Study	IntJInfDis	2000		4	153-157	Azole Itraconazol	V	
378.	Van den Ende, E., van Gompel, A., Stevens, A., Vandeghinste, N., le Ray, D., Gigase, P., de Beule, K., van den Ende, J.	Treatment of CL with oral Itraconazole	IntJDerm	1994	Apr	33 (4)	285-286	Azole Itraconazole	V	X
379.	Vardy, D.	Topical Amphotericin B for CL	Arch Dermatol	1999	July	135	856-857	Ampho	V	
380.	Vardy, D.	Efficacious topical treatment for human CL with ethanolic lipid amphotericin B	Trans R Soc Trop Med Hyg.	2001		95	184-186	Ampho	V	X
381.	Vardy, D.	Treatment of CL – an update	Harefuah	2002	Jan	141(1)	70-75	Übersicht	V	
382.	Velasco- Castrejon, O., Savarino, S., Walton, B., Gam, A., Neva, F.	Diffuse CL in Mexiko	Am J Trop Med Hyg	1989		41(3)	280-88	Diffuse CL	V	X
383.	Velasco-Castrejon, O., Walton, B., Rivas-Sanchez, B., Garcia, M., Lazaro, G., Hobart, O., Roldan, S., Floriani-Verdugo, J., Munguia-Saldana, A., Berzaluze, R.	Treatment of CL with localized current field (radio frequency) in Tabasco, Mexico	Am J Trop Med Hyg	1997		57 (3)	309-312	Heat	v	X
384.	Velez, I., Agudelo, S., Hendrickx, E., Puerta, J., Grogl, M., Modabber, F., Berman, J.	Inefficacy of Allopurinol as Monotherapy for Colombian CL	Ann Int Med	1997	Feb	126(3)	232-236	Allopurinol	V	
385.	Vergel, C., Palacios, R., Cadena, H., Posso, J., Valderrama, L., Perez, M.,	Evidence for Leishmania (Viannia) parasites in the skin and blood of patients before and after	Clin Infect Dis	2006		194	503-511		V	X

	walker, J., Travi, B., Saravia, N.	treatment								
386.	Von Stebut, E.	Immunology of CL: the role of mast cells, phagocytes and dendritic cells for protective immunity	EurJDerm	2007		17(2)	115-122	Immunology	V	X
387.	Wali, J.	Ketoconazole in the Treatment of Antimony- and Pentamidine – Resistant Kala - Azar	J Infect Dis	1992		166	215-216	Azole Ketoconazol	V	
388.	Walsh, D.	OWCL in American soldiers underscores diagnostic and therapeutic options	Expert Rev Derm	2006		1 (3)	355-360	Übersicht	V	X
389.	Weinrauch, L., Cawich, F., Craig, P., Sosa, S., El-On, J.	Topical treatment of NWCL in Belize: a clinical study	J Am Acad Derm	1993	Sept	29	443-446		V	X
390.	Weinrauch, L., Livshin, R.	Ketoconazole in CL	Br J Derm	1997			666-667	Azole	V	X
391.	White, J., Salisbury, J., Path, M., Jones, J., Higgins, E., Vega-Lopez, F.	CL: Three children with Leishmania major successfully treated with Itraconazole	Ped Derm	2006		23	78-80	Azole	V	X
392.	Wiese, M.	Homologues of LMPK, a mitogen – activated protein kinase from <i>Leishmania mexicana</i> , in different <i>Leishmania</i> species	Med Microbiol Immunol	2001		190	19-22	Immunologie	V	
393.	Wiesgigl, M.	The heat shock protein 90 of <i>Leishmania donovani</i>	Med Microbiol Immunol	2001		190	27-31		V	
394.	Wortmann, G.	A randomized, Double-Blind Study of the Efficacy of a 10 or 20 Day Course of Sodium Stibogluconate for Treatment of CL in United States Military Personnel	Clin Infect Dis	2002		35	261-67	Antimon	V	X
395.	Wortmann, G.	Boiling the boil	Clin Infect Dis	2005	Apr	40	1156-1158	Heat	V	X
396.	Wortmann, G.	CL following Local Trauma: A Clinical Pearl	Clin Infect Dis	2000		31	199-201	Klinik	V	X
397.	Wortmann, G.	Failure of amphotericin B lipid in the treatment of CL	Clin Infect Dis	1998	Apr	26 (4)	1006-1007	Liposomal ampho	A	X
398.	Wortmann GW, Cummings	Visceral leishmaniasis: clinical	Arch Intern	2007	Sep	24;167(17)	1899-901			

	JF, Barthel RV, Patel S, Crum-Cianflone NF, Negin NS, Weina PJ, Ockenhouse CF, Joyce DJ, Magill AJ, Aronson NE, Gasser RA Jr.	observations in 4 US army soldiers deployed to Afghanistan or Iraq, 2002-2004	Med							
399.	Wortmann, G., Hochberg, L., Arana, B., Rizzo, N., Arana, F., Ryan, J.	Diagnosis of CL in Guatemala using a real-time polymerase chain reaction and the smartcycler	Am. J. Trop Med Hyg	2007		76(5)	906-908	Diagnostik	V	X
400.	Wunsch, H.	Cocktail vaccine shows promise for CL	Lancet	1998	May	351	1495		V	
401.	Yardley, V.	Activity of Liposomal Amphotericin B against experimental CL	Antimicrob Agents Chemother	1997	April	41(4)	752-56	Liposomal Ampho	V	X
402.	Yardley, V.	A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and CL	IntJ Antimicrob Agents	2000		13	243-248	Liposomal Ampho	V	
403.	Yardley, V.	The Sensitivity of clinical Isolates of Leishmania from Peru and Nepal to Miltefosine	Am J. Trop Med Hyg.	2005		73(2)	272-275	Miltefosine	V	X
404.	Zeegelaar, J., Steketeer, W., van Thiel, P., Wetsteyn, J., Kager, P., Faber, W.	Changing pattern of imported Leishmaniasis in the Netherlands	Clin Exp Derm	2005		30	1-5	Epidemiology	V	X
405.	Zerpa, O., Ulrich, M., Blanco, B., et al	Diffuse CL responds to miltefosine but then relapses	Br J Derm	2007	Apr	17		Miltefosine	A	

Abkürzungen

ACL	American cutaneous Leishmaniasis
CL	Cutaneous Leishmaniasis
MCL	Muco-kutane Leishmaniasis
NWCL	New World Cutaneous Leishmaniasis
OWCL	Old World Cutaneous Leishmaniasis
VL	Viszeral Leishmaniasis